ArticleMolecular biology reports2025
The possible role of hsa_circ_0049356 and hsa-miR-338-3p in systemic lupus erythematosus disease.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) is an autoimmune disease characterized by a variety of clinical manifestations and a relapsing-remitting course. MiR-338-3p has emerged as a significant regulator of the immune response in the pathogenesis of SLE. Hsa_circ_0049356 is a circular RNA that may serve as a potential biological or clinical marker for autoimmune disorders. PURPOSE OF THE STUDY: This study aims to evaluate the potential role of hsa_circ_0049356 and miR-338-3p in the pathogenesis of SLE by analyzing their expression patterns and assessing their impact on the ERK/MAPK signaling pathway. Understanding these interactions may provide novel insights into the pathogenesis of SLE and identify potential diagnostic or therapeutic targets.
methodsThis study included 100 participants, divided into two groups: healthy controls and SLE patients. Comprehensive clinical evaluations, including history taking, physical examination, and laboratory investigations, were performed. The expression levels of hsa_circ_0049356 and miR-338-3p were determined using RT-PCR. Additionally, the levels of SIRT6, ERK, MAPK, and MEK-1 were measured using Enzyme Linked Immunosorbent Assay.
resultsThe expression of hsa_circ_0049356 and the level of SIRT6 were significantly decreased in SLE patients. Moreover, SLE patients exhibited increased miR-338-3p expression and higher levels of ERK, MAPK, and MEK-1 compared to healthy controls.
conclusionThis study suggests that the release of sponge effect of hsa_circ_0049356 on miR-338-3p leads to an increase in miR-338-3p, which may contribute to the pathogenesis of SLE by modulating the ERK/MAPK pathway.
Indexed as
Identifiers
40608140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.